Hamilton Lane Advisors LLC lessened its holdings in Intersect ENT Inc (NASDAQ:XENT) by 31.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,560 shares of the medical equipment provider’s stock after selling 10,000 shares during the period. Hamilton Lane Advisors LLC’s holdings in Intersect ENT were worth $699,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. bought a new position in Intersect ENT in the third quarter valued at about $117,000. Great West Life Assurance Co. Can bought a new position in Intersect ENT in the third quarter valued at about $116,000. Bank of Montreal Can bought a new position in Intersect ENT in the fourth quarter valued at about $135,000. Legal & General Group Plc grew its position in Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after acquiring an additional 255 shares during the last quarter. Finally, Moors & Cabot Inc. bought a new position in Intersect ENT in the second quarter valued at about $205,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.
Intersect ENT Inc (NASDAQ XENT) traded up $0.15 during trading hours on Wednesday, hitting $33.95. The stock had a trading volume of 228,632 shares, compared to its average volume of 316,318. The company has a market capitalization of $1,000.00, a PE ratio of -54.76 and a beta of 0.67. Intersect ENT Inc has a 52 week low of $11.75 and a 52 week high of $35.34.
Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. The company had revenue of $22.31 million for the quarter, compared to analysts’ expectations of $21.53 million. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The business’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.22) earnings per share. sell-side analysts forecast that Intersect ENT Inc will post -0.63 earnings per share for the current year.
XENT has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research report on Thursday, October 5th. Guggenheim reiterated a “buy” rating and issued a $41.00 target price on shares of Intersect ENT in a research report on Friday, December 15th. Canaccord Genuity reiterated a “buy” rating and issued a $36.00 target price on shares of Intersect ENT in a research report on Monday, December 11th. BidaskClub cut Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Finally, BTIG Research restated a “hold” rating on shares of Intersect ENT in a report on Tuesday, November 7th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Intersect ENT presently has an average rating of “Buy” and a consensus price target of $33.38.
In related news, Director Frederic H. Moll sold 6,700 shares of Intersect ENT stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $28.77, for a total value of $192,759.00. Following the transaction, the director now directly owns 247,124 shares of the company’s stock, valued at $7,109,757.48. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Lisa D. Earnhardt sold 10,685 shares of Intersect ENT stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $31.87, for a total value of $340,530.95. Following the completion of the transaction, the insider now directly owns 487,868 shares in the company, valued at $15,548,353.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 116,886 shares of company stock worth $3,663,594. Company insiders own 13.70% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Intersect ENT Inc (XENT) Holdings Cut by Hamilton Lane Advisors LLC” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/18/intersect-ent-inc-xent-holdings-cut-by-hamilton-lane-advisors-llc.html.
Intersect ENT Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT Inc (NASDAQ:XENT).
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.